ArticleCureus2026
Expression of the Cystatin SN (CST1) in Breast Cancer and Its Association With Clinical Characteristics: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Breast cancer is a major global health concern with increasing incidence and mortality, particularly in low- and middle-income countries such as Bangladesh. Cystatin SN (CST1) has emerged as a potential oncogenic biomarker; however, its expression and clinical relevance remain underexplored in Bangladeshi populations. This study aimed to evaluate CST1 expression in tumor and adjacent normal breast tissues and to assess its association with the clinical characteristics of breast cancer patients. Methods A hospital-based cross-sectional study was conducted at Dhaka Medical College, Bangladesh, from January 2023 to June 2023. A total of 34 adult female patients (aged 25-70 years) with histologically confirmed, treatment-naïve breast cancer were recruited via purposive sampling. Paired tumor and adjacent normal tissue samples were collected following a modified radical mastectomy. CST1 gene expression was measured via next-generation sequencing. The data were analyzed via SPSS version 26 (IBM Corp., Armonk, NY, USA). The Wilcoxon signed-rank test was used to compare gene expression between paired samples, and Spearman's correlation coefficient was applied to assess associations with clinical variables. Results The mean age of the participants was 47.41 ± 12.19 years. CST1 gene expression was significantly greater in tumor tissue than in adjacent normal tissue (median -0.068 vs -1.988, p = 0.035). A statistically significant positive association was observed between CST1 expression and a family history of breast cancer (rho = 0.267, p = 0.027). In contrast, CST1 expression was significantly negatively associated with contraceptive use (rho = -0.437, p < 0.001) and weakly negatively associated with breastfeeding history (rho = -0.240, p = 0.049). No significant associations were observed between CST1 expression and age, body mass index, parity, or age at menarche. Conclusion CST1 gene expression is significantly elevated in tumor tissue and is associated with selected clinical factors, suggesting its potential relevance as a molecular marker in breast cancer. Further large-scale and longitudinal studies are needed to establish its clinical and prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.